Donald Kalff

After receiving his PhD from the Wharton School of the University of Pennsylvania, Donald Kalff spent most of his professional life as a manager at Royal Dutch Shell and as a member of the Executive Board of KLM, Royal Dutch Airlines.

During the last 15 years, he co-founded AIMM Therapeutics, a biotech company that generates antibodies against infectious diseases and cancer with unique proprietary technologies and he also founded MondialDx, a company which markets and develops diagnostic tests for tropical diseases. Moreover, he participates in two companies that develop more effective formulas for medicines for skin diseases and women’s health in the tropics. He has also invested in two companies in the field of cyber security.

Donald Kalff is the author of three books and numerous articles on the governance and management of large enterprises and on the competitiveness of Europe. His next book is scheduled to appear in 2020.

He is a member of the board of the Dutch chapter of Transparency International, the largest anti-corruption network in the world.

Education

• Doctor of Philosophy - PhD The Wharton School
• Master of Business Administration - MBA Rotterdam School of Management, Erasmus University
• Bachelor's degree Vrije Universiteit Amsterdam (VU Amsterdam)

Companies

• Member of the Board Transparency International (2018)
• Founder Mondial Diagnostics (2016)
• Owner and Managing Director Cattus Baanbrekend Advies (2010)
• Co-Founder AIMM Therapeutics (2009 — 2018)
• Senior Fellow The Wharton School (2008 — 2013)
• Independent writer, thinker, entrepreneur Kogan Page (2002 — 2010)
• Member of the Executive Board KLM Royal Dutch Airlines (1990 — 2002)
• Planning Manager Shell (1980 — 1990)
• Assistant Professor Rotterdam School of Management, Erasmus University (1974 — 1980)